Tempest Therapeutics, Inc. (TPST) is a Pharmaceutical Preparations stock trading at $1.54 (as of 2026-05-29), with a market capitalization of $17.10M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Tempest Therapeutics, Inc. is a clinical-stage oncology company developing small-molecule therapies. Its pipeline includes TPST-1495, a dual antagonist of EP2/EP4 in a Phase 1 solid-tumor trial, and TPST-1120, a selective PPARα antagonist also in a Phase 1 solid-tumor trial, alongside TREX-1 for regulating innate immune responses in tumors.
| Price | $1.54 |
| Market Cap | $17.10M |
| EV / EBITDA | -0.5 |
| Price / Book | -15.69 |
| FCF Yield | -121.2% |
| Revenue (TTM) | $295000.00 |
| Net Margin | -17279.7% |
| Return on Equity | 3713.0% |
| Debt / Equity | -3.85 |
| Current Ratio | 0.38 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -99.6% |
| FCF Growth (YoY) | 16.4% |
| Top Institutional Holder | VANGUARD GROUP INC ($466547.00) |
| Institutional Holders Tracked | 10 |
| Sector | Pharmaceutical Preparations |
| Industry | Pharmaceutical Preparations |
| CEO | Matthew Angel |
| Employees | 24 |
| Country | US |
| IPO Date | 2012-11-12 |
Data as of 2026-05-29.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.